The guideline summarized in this manuscript has been endorsed by the Multi-National Association for Supportive Care in Cancer and the C17 Research Network.
Clinical Practice Guideline
Article first published online: 19 MAR 2013
Copyright © 2013 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 7, pages 1073–1082, July 2013
How to Cite
Dupuis, L. L., Boodhan, S., Holdsworth, M., Robinson, P. D., Hain, R., Portwine, C., O'Shaughnessy, E. and Sung, L. (2013), Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr. Blood Cancer, 60: 1073–1082. doi: 10.1002/pbc.24508
Conflict of interest: Nothing to declare.
- Issue published online: 22 MAY 2013
- Article first published online: 19 MAR 2013
- Manuscript Accepted: 29 JAN 2013
- Manuscript Received: 11 SEP 2012
- Pediatric Oncology Group of Ontario
- Ministry of Health and Long Term Care, Ontario
- Children's Oncology Group
- antineoplastic-induced nausea and vomiting;
- chemotherapy-induced nausea and vomiting;
This guideline provides an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children. It was developed by an international, inter-professional panel using AGREE and CAN-IMPLEMENT methods. Evidence-based interventions that provide optimal AINV control in children receiving antineoplastic agents of high, moderate, low, and minimal emetogenicity are recommended. Recommendations are also made regarding selection of antiemetic agents for children who are unable to receive corticosteroids for AINV control, the role of aprepitant and optimal doses of antiemetic agents. Gaps in the evidence used to support the recommendations were identified. The contribution of this guideline to AINV control in children requires prospective evaluation. Pediatr Blood Cancer 2013; 60: 1073–1082. © 2013 Wiley Periodicals, Inc.